TISIDB

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Cell membrane Peripheral membrane protein
Domain	PF09380 FERM C-terminal PH-like domain PF00373 FERM central domain PF09379 FERM N-terminal domain
Function	E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR.

> Gene Ontology [ TOP ]
Biological Process	GO:0000209 protein polyubiquitination GO:0009894 regulation of catabolic process GO:0009896 positive regulation of catabolic process GO:0010984 regulation of lipoprotein particle clearance GO:0010985 negative regulation of lipoprotein particle clearance GO:0010988 regulation of low-density lipoprotein particle clearance GO:0010989 negative regulation of low-density lipoprotein particle clearance GO:0031329 regulation of cellular catabolic process GO:0031647 regulation of protein stability GO:0031648 protein destabilization GO:0032799 low-density lipoprotein receptor particle metabolic process GO:0032801 receptor catabolic process GO:0032802 low-density lipoprotein particle receptor catabolic process GO:0032803 regulation of low-density lipoprotein particle receptor catabolic process GO:0034381 plasma lipoprotein particle clearance GO:0034383 low-density lipoprotein particle clearance GO:0042176 regulation of protein catabolic process GO:0042632 cholesterol homeostasis GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:0043112 receptor metabolic process GO:0045732 positive regulation of protein catabolic process GO:0055088 lipid homeostasis GO:0055092 sterol homeostasis GO:0097006 regulation of plasma lipoprotein particle levels GO:1903362 regulation of cellular protein catabolic process GO:2000644 regulation of receptor catabolic process
Molecular Function	GO:0004842 ubiquitin-protein transferase activity GO:0016874 ligase activity GO:0019787 ubiquitin-like protein transferase activity GO:0061630 ubiquitin protein ligase activity GO:0061659 ubiquitin-like protein ligase activity
Cellular Component	GO:0019898 extrinsic component of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-983168: Antigen processing R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-168256: Immune System R-HSA-73923: Lipid digestion, mobilization, and transport R-HSA-174824: Lipoprotein metabolism R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-8855121: VLDL interactions R-HSA-8866427: VLDLR internalisation and degradation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-8855121: VLDL interactions
R-HSA-8866427: VLDLR internalisation and degradation

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MYLIP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MYLIP in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -1.92; FDR: 0.03680	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MYLIP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.195	0.521
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.269	0.885
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.139	0.921
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.475	0.303
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.309	0.857
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.688	0.758
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.016	0.963
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.517	0.757
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.486	0.786
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.679	0.587
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.435	0.436
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.214	0.0978

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MYLIP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYLIP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYLIP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYLIP. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYLIP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MYLIP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MYLIP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MYLIP
Name	myosin regulatory light chain interacting protein
Aliases	IDOL; E3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor; band 4.1 superfamily m ......
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MYLIP collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MYLIP